Category: CBDiary

Epidiolex Success Makes the NY Times

March 15, 2016  The front page of today’s New York Times business section includes a clearly written, accurate story by Andrew Pollack about GW Pharmaceuticals’ Epidiolex achieving a significant level of seizure reduction in a hospital-based clinical trial.  GW will now seek FDA approval based on the favorable results of this trial. Pollack notes: The F.D.A. has been sending warning letters to some companies, many of them selling hemp oil, saying that they are illegally marketing their products as drugs and that cannabidiol cannot be sold as a dietary supplement because it is being studied for use as a drug. GW stock...

Read More

Epidiolex Achieves its Goal in Phase 3 Trial

March 14, 2016   GW Pharmaceuticals announced today that its Phase 3 clinical trial of Epidiolex —a plant extract with cannabinoid content that is 99% cannabidiol (CBD)— has met its primary endpoint in reducing seizures in Dravet syndrome patients. Almost certainly, the FDA will now acknowledge that compounds in Cannabis have medical benefit, and the plant’s status on Schedule I of the federal Controlled Substance Act will become untenable. (As if it hasn’t been all these years!)  O’Shaughnessy’s current issue provides the broad context of the story.  The following is from GWP’s March 14 press release, which caused its stock to more...

Read More

Cannabis use Promotes Physical Fitness!

By Fred Gardner Another newsworthy study that didn’t make the news has been brought to our attention: The Effect of Medical Marijuana Laws on Body Weight by San Diego State policy analyst Joseph J. Sabia and colleagues. Now that more than 20 states have enacted medical marijuana laws (MMLs), “big data” can be compiled and correlations made between marijuana use and impacts on the population. It turns out that access to the herb leads to a measurably leaner citizenry! Sabia et al attribute the result to two mechanisms: young adults using marijuana as a substitute for alcohol, and those over 35 getting pain relief enabling them to exercise more. ...

Read More

Cannabis as a treatment for autism

The Israeli filmmaker Zach Klein is following up his Raphael Mechoulam biopic The Scientist with a documentary about cannabis as a treatment for autism. I received this note from Klein, along with an image from his new project: I’m editing my documentary about autism (and cannabis) and I think that Mechoulam is looking at O’Shaughnessy’s. Picture is attached. Did you publish something about the subject? The page from O’Shaughnessy’s  that Mechoulam was looking was from our Summer 2009 issue. It contained two brief case reports by Philip Denney, MD.  A colleague of Mechoulam’s had evidently put the page in an envelope and mailed it...

Read More

Senate Drug Caucus Holds Hearing on CBD

By Fred Gardner The Senate Caucus on International Narcotics Control was created in 1985 (the height of the Ronald Reagan era) and given special powers to issue subpoenas and call hearings. Chairman Chuck Grassley (Republican, Iowa), arranged for a hearing June 24, 2015 on “Barriers to Cannabidiol Research and Potential Medical Benefits.” After opening statements by Grassley and his Democratic counterpart, Dianne Feinstein of California, three Senators who have introduced CBD-related bills —Orrin Hatch, Kirsten Gillibrand, and Cory Booker laid out their views. Then came testimony by Joe Rannazzasi of the DEA, Dr. Douglas Throckmorton a deputy director at FDA,...

Read More